99 reports

Global Laboratory Reagents Industry LABORATORY REAGENTS MCP-## MARKET ANALYSIS, TRENDS, AND FORECASTS, MAY ## CONTENTS ##.

  • Protein Therapy
  • APAC
  • Japan
  • United States
  • World

For instance, as per the Alliance for Regenerative Medicine 2019 report, there are ## regenerative medicine companies worldwide sponsoring ##, ## active clinical trials.

  • Protein Therapy
  • North America
  • World
  • Forecast
  • Sartorius Stedim Biotech S.A.

Most of the reactions in cells and organisms are catalyzed by enzymes that are regenerated during the course of a reaction.

  • Protein Therapy
  • North America
  • United States
  • Market Size
  • DuPont

Comprehensive understanding of β-cell function and pathology will therefore be vital for the future development of successful preventative or regenerative therapies.

  • Diabetes
  • Insulin
  • Protein Therapy
  • Therapy
  • World

Take bioengineering medicine as main one and natural medicine and medicine preparation as supplement.

  • Protein Therapy
  • China
  • Demand
  • Market Size
  • Supply
  • HEMOADSORPTION DEVICE - SEPSIS - PRODUCT DESCRIPTION

McGowan educates scientists and engineers developing technologies related to regenerative medicine and trains clinicians in the use of regenerative therapies.

  • Blood Supply
  • Clinical Trial
  • Protein Therapy
  • United States
  • CytoSorbents Corporation
  • System Type

THIS FOUNDATION IS AIMED AT PROMOTING, SUPPORTING, AND CONDUCTING RESEARCH AND INNOVATION IN THE FIELDS OF BIOTECHNOLOGY, REGENERATIVE MEDICINE, NEW DRUGS AND VACCINES, NEW-GENERATION MEDICAL DEVICES, AND THERAPIES FOR BRAIN DISORDERS.

  • Biotechnology
  • Cell Therapy
  • Pharmaceutical
  • Protein Therapy
  • Proteomics

THE PIPELINE FOCUSES ON NOVEL PHARMACOLOGIC DRUGS & REGENERATIVE MEDICINES COVERING SMALL MOLECULES, ANTIBODIES, STEM CELL THERAPIES, RECOMBINANT PROTEINS AND RNA-BASED THERAPEUTICS, BUT EXCLUDES SYMPTOM RELIEF DRUGS, GENERIC COMBINATIONS AND SUPPLEMENTAL DRUGS.

  • Protein Therapy
  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cerenis
  • ATROSIMAB - DRUG PROFILE

Through the investment in Promethera SA, ITOCHU will support the expansion of Promethera SA s business in regenerative medicine.

  • Immunotherapy
  • Monoclonal Antibody
  • Protein Therapy
  • Therapy
  • Promethera Biosciences S.A.
  • ATROSIMAB - DRUG PROFILE

It has partnership with other oncology medicine center.

  • Immunotherapy
  • Medical Biotechnology
  • Monoclonal Antibody
  • Protein Therapy
  • Therapy

The company provides out-licensing and in-licensing opportunities for severe diseases, orphan and regenerative medicine indications.

  • Cancer
  • Clinical Trial
  • Pharmaceutical
  • Protein Therapy
  • Therapy
  • Clinical Trial profile. 280 Trial Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Mouth Disease
  • Protein Therapy
  • World
  • FORTUNEROCK (CHINA) LTD

Funding for the LAUNCH trial is supported by a USD ##. ## million grant from the California Institute for Regenerative Medicine. subsequent cycles of chemotherapy.

  • Chemotherapy
  • Monoclonal Antibody
  • Pharmaceutical
  • Protein Therapy
  • Therapy

Food and Drug Administration and European Medicines Agency.

  • Blood Disease
  • Protein Therapy
  • United States
  • Product Initiative
  • uniQure N.V.

The prominent features of this report are - ##.

  • Clinical Trial
  • Mouth Disease
  • Protein Therapy
  • World
  • Colgate-Palmolive Company

Food and Drug Administration and European Medicines Agency.

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • United States
  • PLXR-18 - DRUG PROFILE
  • PLXR-18 - DRUG PROFILE

Pluristem Therapeutics, Inc. announced that it has renewed a five-year collaborative research agreement with the Berlin-Brandenburg Center for regenerative therapy (BCRT) at Charite University Medicine Berlin.

  • Protein Therapy
  • Therapy
  • United States
  • Product Initiative
  • Pluristem Therapeutics Inc.

THE PROGENITOR CELLS TO TREAT FULMINANT HEPATITIS BY PROCUREMENT OF A POOL OF DIVIDING AND FUNCTIONING CELLS TO PROMOTE LIVER REGENERATION.

  • Blood Disease
  • Protein Therapy
  • Therapy
  • United States
  • Product Initiative

Pestell, M. D., Ph. D., President of the Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S.

  • HIV AIDS
  • HIV Antiviral
  • Pathology
  • Protein Therapy
  • Therapy
  • HEMOPHILIA A (FACTOR VIII DEFICIENCY) - PIPELINE BY IMMUSOFT CORP, H2 2019
  • HEMOPHILIA A (FACTOR VIII DEFICIENCY) - PIPELINE BY INNOVARE R & D SA DE CV, H2 2019

The company develops regenerative medicines, cell therapy and other bio products.

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • United States
  • Target

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiology
  • Clinical Trial
  • Hospital
  • Medical Biotechnology
  • Protein Therapy

Previously reldesemtiv was granted orphan drug designation for the treatment of spinal muscular atrophy (SMA) by the FDA and by the European Medicines Agency.

  • Clinical Trial
  • Dementia
  • Hospital
  • Neurology
  • Protein Therapy

regenerative medicine products in the new biotech business.

  • Blood Disease
  • Pathology
  • Pharmaceutical
  • Protein Therapy
  • Therapy

## ## ## ## ## ## ## ## MallInckrodt Plc ## ## ## ## ## ## ## ## Syneos Health Inc ## ## ## ## ## ## ## ## Sun Pharmaceutical Industries Ltd ## ## ## ## ## ## ## ## Pfizer Inc Noveome Biotherapeutics Inc Fresenius SE & Co KGaA Fibrocell Science Inc Bayer AG ##

  • Clinical Trial
  • Protein Therapy
  • Therapy
  • World
  • MediWound Ltd.

Pestell, M. D., Ph. D., President of the Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S.

  • Antiviral
  • HIV AIDS
  • HIV Antiviral
  • Protein Therapy
  • Therapy

The prominent features of this report are - ##.

  • Clinical Trial
  • Dementia
  • Immunotherapy
  • Neurology
  • Protein Therapy
  • PIPELINE BY CYTOVIA INC, H2 2018
  • PIPELINE BY CANTEX PHARMACEUTICALS INC, H2 2018

The company provides drug portfolio within the field of pharmaceutical regenerative medicine.

  • Immunotherapy
  • Medical Biotechnology
  • Pharmaceutical
  • Protein Therapy
  • Therapy
  • Target

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Clinical Trial
  • Medical Biotechnology
  • Monoclonal Antibody
  • Protein Therapy

Hoffmann-La Roche Ltd AstraZeneca Plc Guangzhou Reborn Health Management Consultation Co Ltd Inovio Pharmaceuticals Inc RedHill Biopharma Ltd Pfizer Inc Azidus Laboratories Ltd Incyte Corp ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Clinical Trial
  • Pharmaceutical
  • Protein Therapy
  • China
  • World
  • RECOMBINANT PROTEIN TO ANTAGONIZE TGF BETA FOR IMMUNOLOGY, DERMATOLOGY, GASTROINTESTINAL AND MUSCULOSKELETAL DISORDERS - DRUG PROFILE

IT IS BEING DEVELOPED BASED ON REGENERATIVE MEDICINE TECHNOLOGY.

  • Medical Supply
  • Protein Therapy
  • Wound Care
  • United States
  • Product Initiative